A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

被引：10
|
作者：
Kaddoura, Rasha [1 ]
Dabdoob, Wafer A. A. [1 ]
Ahmed, Khalid [1 ]
Yassin, Mohamed A. A. [1 ]
机构：
[1] Hamad Med Corp, Doha, Qatar
来源：
FRONTIERS IN MEDICINE | 2023年 / 10卷
关键词：
chronic myeloid leukemia; tyrosine kinase; heart failure; pulmonary arterial hypertension; QT prolongation; dasatinib; ponatinib; pleural effusion; MAJOR MOLECULAR RESPONSE; CHRONIC PHASE; CARDIOVASCULAR EVENTS; NILOTINIB; IMATINIB; HYPERTENSION; POPULATION; MANAGEMENT; DASATINIB; SAFETY;
D O I：
10.3389/fmed.2023.1163137
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) but their use was associated with a range of serious cardiopulmonary toxicities including vascular adverse events, QT prolongation, heart failure, pleural effusion, and pulmonary arterial hypertension. Dedicated clinical management guidelines for TKI-induced toxicities are not available. This review aims to discuss TKI-associated cardiopulmonary toxicities and proposes a practical guide for their management.
引用
收藏
页数：19
相关论文
共 50 条
  • [1] Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia
    Quintas-Cardama, Alfonso
    Cortes, Jorge E.
    Kantarjian, Hagop
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 : S82 - S88
  • [2] A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia
    Ahmed, Khalid
    Kaddoura, Rasha
    Yassin, Mohamed A. A.
    FRONTIERS IN MEDICINE, 2022, 9
  • [3] Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia
    Mathisen, Michael S.
    Kantarjian, Hagop M.
    Cortes, Jorge
    Jabbour, Elias J.
    BLOOD REVIEWS, 2014, 28 (05) : 179 - 187
  • [4] Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
    Garcia-Gutierrez, Valentin
    Carlos Hernandez-Boluda, Juan
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [5] Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
    Haznedaroglu, Ibrahim C.
    TURKISH JOURNAL OF HEMATOLOGY, 2013, 30 (03) : 247 - 255
  • [6] WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
    Haznedaroglu, Ibrahim C.
    Kuzu, Isinsu
    Ilhan, Osman
    TURKISH JOURNAL OF HEMATOLOGY, 2020, 37 (01) : 42 - 47
  • [7] Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
    Yoshifuji, Kota
    Sasaki, Koji
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
    DeAngelo, D. J.
    BLOOD CANCER JOURNAL, 2012, 2 : e95 - e95
  • [9] Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
    Garcia-Gutierrez, Valentin
    Hernandez-Boluda, Juan Carlos
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 14
  • [10] Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment
    Chelysheva, Ekaterina
    Turkina, Anna
    Polushkina, Evgenia
    Shmakov, Roman
    Zeifman, Alexey
    Aleshin, Sergey
    Shokhin, Igor
    Guranda, Dorel
    Oksenjuk, Oksana
    Mordanov, Sergey
    Kazakbaeva, Khamida
    Chilov, Ghermes
    LEUKEMIA & LYMPHOMA, 2018, 59 (03) : 733 - 738
12345